Abstract
This study examined the effect of tamoxifen, an anti-breast cancer drug, on Ca2+ handling in bladder female transitional cancer cells. Changes in cytosolic free Ca2+ levels were recorded by using the Ca2+-sensitive dye fura-2. In a dose-dependent manner, tamoxifen induced intracellular free Ca2+ concentrations ([Ca2+]i) increases between 5 and 20 μM with an EC50 of 10 μM. External Ca2+ removal reduced the response by 60±6%. Addition of 3 mM Ca2+ caused a [Ca2+]i increase after pretreatment with 10 μM tamoxifen in Ca2+-free medium. In Ca2+-free medium, pretreatment with 10 μM tamoxifen abolished the [Ca2+]i increase induced by 1 μM thapsigargin, an endoplasmic reticulum Ca2+ pump inhibitor. Conversely, pretreatment with 1 μM thapsigargin prevented tamoxifen from releasing more Ca2+. Inhibition of phospholipase C-dependent inositol 1,4,5-tris-phosphate formation with 2 μM U73122 did not alter 10 μM tamoxifen-induced Ca2+ release. The [Ca2+]i increase induced by 5 μM tamoxifen was not altered by 10 μM La3+, nifedipine, verapamil, and diltiazem. Collectively, it was found that tamoxifen increased [Ca2+]i in bladder cancer cells by releasing Ca2+ from the endoplasmic reticulum Ca2+ stores in a manner independent of phospholipase C activity, and by inducing Ca2+ entry from external medium.
Original language | English |
---|---|
Pages (from-to) | 184-188 |
Number of pages | 5 |
Journal | Archives of Toxicology |
Volume | 75 |
Issue number | 3 |
DOIs | |
State | Published - 2001 |
Externally published | Yes |
Keywords
- BFTC cells
- Bladder cell carcinoma
- Ca signaling
- Fura-2
- Tamoxifen